Zine News

Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial

MELBOURNE, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of the clinical study conducted by the TREAT Consortium which was funded by the National Institute of Alcohol Abuse and Alcoholism (NIAAA).

Publicaciones relacionadas

Botón volver arriba